title: Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
abstract: Activation of the fibrinolytic pathway has long been associated with human breast cancer. Plasmin is the major end product of the fibrinolytic pathway and is critical for normal physiological functions. The mechanism by which plasmin is generated in breast cancer is not yet fully described. We previously identified annexin II (ANX II), a fibrinolytic receptor, in human breast tumor tissue samples and observed a strong positive correlation with advanced stage cancer (Sharma et al., 2006a). We further demonstrated that tissue plasminogen activator (tPA) binds to ANX II in invasive breast cancer MDA-MB231cells, which leads to plasmin generation (Sharma et al., 2010). We hypothesize that ANX II-dependent plasmin generation in breast tumor is necessary to trigger the switch to neoangiogenesis, thereby stimulating a more aggressive cancer phenotype. Our immunohistochemical studies of human breast tumor tissues provide compelling evidence of a strong positive correlation between ANX II expression and neoangiogenesis, and suggest that ANX II is a potential target to slow or inhibit breast tumor growth by inhibiting neoangiogenesis. We now report that administration of anti-ANX II antibody potently inhibits the growth of human breast tumor in a xenograft model. Inhibition of tumor growth is at least partly due to attenuation of neoangiogenic activity within the tumor. In vitro studies demonstrate that anti-ANX II antibody inhibits angiogenesis on three dimensional matrigel cultures by eliciting endothelial cell (EC) death likely due to apoptosis. Taken together, these data suggest that selective disruption of the fibrinolytic activity of ANX II may provide a novel strategy for specific inhibition of neoangiogenesis in human breast cancer.
authors: University of Pennsylvania, School of Medicine, PA, USA.
authors: Meena
authors: M
authors: Sharma
authors: Marc R
authors: MR
authors: Blackman
authors: Mahesh C
authors: MC
authors: Sharma
mesh_terms: D000818:Animals; D017306:Annexin A2 / Q000276:immunology* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000276:immunology; D001940:Breast / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000098:blood supply* / Q000276:immunology / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D005341:Fibrinolysin / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D010641:Phenotype; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism; D014183:Transplantation, Heterologous
chemical_list: D017306:Annexin A2; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin